Screen of existing drugs finds compounds active against MERS coronavirus
Clinicians treating patients suffering from Middle East respiratory syndrome (MERS) currently have no drugs specifically targeted to the MERS coronavirus (MERS-CoV), a virus first detected in humans in 2012. To address the urgent need for therapies, screened a set of 290 compounds already approved by the US Food and Drug Administration or far advanced in clinical development for other indications to determine if any might also show potential for working against MERS-CoV.
Source: ScienceDaily Headlines - Category: Science Source Type: news
More News: Coronavirus | Food and Drug Administration (FDA) | MERS | Middle East Health | Respiratory Medicine | Science